FOXM1 and hepatocellular carcinoma: Nevertheless, our data suggested that advanced AFP-positive HCC patients may receive a survival benefit by the addition of a reagent targeting FOXM1, such as carfilzomib, in combination with anti-VEGFR2 antibody treatment.